MK-0524A + MK-0524A

Phase 1Terminated

1 views this week 0 watching💤 Quiet

Interest: 21/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Hypercholesterolemia, Familial

Conditions

Hypercholesterolemia, Familial, Heterozygous Familial Hypercholesterolemia

Trial Timeline

Jun 1, 2012 → Dec 1, 2012

NCT ID

NCT01583647

About MK-0524A + MK-0524A

MK-0524A + MK-0524A is a phase 1 stage product being developed by Merck for Hypercholesterolemia, Familial. The current trial status is terminated. This product is registered under clinical trial identifier NCT01583647. Target conditions include Hypercholesterolemia, Familial, Heterozygous Familial Hypercholesterolemia.

What happened to similar drugs?

20 of 20 similar drugs in Hypercholesterolemia, Familial were approved

Approved (20) Terminated (2) Active (0)

✅generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)YuhanApproved

✅Rosuvastatin+Ezetimibe + RosuvastatinYuhanApproved

✅colesevelam HCl tablets, and simvastatin tablets + simvastatin tablets and colesevelam HCl placeboDaiichi SankyoApproved

✅colesevelam HCl tablets and fenofibrate tablets + fenofibrate tablets and Welchol placebo tablets + fenofibrate tablets and Welchol placebo tabletsDaiichi SankyoApproved

✅colesevelam HCl + placeboDaiichi SankyoApproved

✅colesevelam HCl tablets, and atorvastatin tablets + colesevelam HCl placebo tablets and atorvastatin tabletsDaiichi SankyoApproved

✅Bempedoic acid 180 mg tabletDaiichi SankyoApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01583647	Phase 1	Terminated	Jun 1, 2012	Dec 1, 2012	Hypercholesterolemia, Familial

Competing Products

20 competing products in Hypercholesterolemia, Familial

See all competitors

Product	Company	Stage	Hype Score
Evacetrapib + Ezetimibe + Atorvastatin + Placebo	Eli Lilly	Phase 3	32
generic formulation of atorvastatin (Atorva®) + branded formulation of atorvastatin (Lipitor®)	Yuhan	Approved	43
Rosuvastatin+Ezetimibe + Rosuvastatin	Yuhan	Approved	43
colesevelam HCl tablets, and simvastatin tablets + simvastatin tablets and colesevelam HCl placebo	Daiichi Sankyo	Approved	43
colesevelam HCl tablets and fenofibrate tablets + fenofibrate tablets and Welchol placebo tablets + fenofibrate tablets and Welchol placebo tablets	Daiichi Sankyo	Approved	43
colesevelam HCl + placebo	Daiichi Sankyo	Approved	43
Bempedoic acid and/or its fixed-dose combination with ezetimibe	Daiichi Sankyo	Pre-clinical	30
colesevelam HCl tablets, and atorvastatin tablets + colesevelam HCl placebo tablets and atorvastatin tablets	Daiichi Sankyo	Approved	43
Bempedoic acid 180 mg tablet	Daiichi Sankyo	Approved	43
Bempedoic Acid 180Mg/Ezetimibe 10Mg Tab	Daiichi Sankyo	Pre-clinical	26
Colesevelam Hydrochloride + Ezetimibe + Simvastatin	Daiichi Sankyo	Approved	43
pravastatin tablets and Welchol tablets + pravastatin tablets and Welchol placebo tablets	Daiichi Sankyo	Approved	43
Bempedoic acid and/or its fixed dose combination with ezetimibe	Daiichi Sankyo	Pre-clinical	18
atrovastatin	Astellas Pharma	Pre-clinical	26
Pitavastin 4mg + Atorvastatin 20mg + Rosuvastatin 5mg	Eli Lilly	Approved	43
PPAR alpha + atorvastatin + placebo	Eli Lilly	Phase 2	35
Evacetrapib + Placebo	Eli Lilly	Phase 3	32
LY3015014 + Placebo + Statin + Ezetimibe	Eli Lilly	Phase 2	35
SHR-1209 single-site subcutaneous injection + SHR-1209 multiple-site subcutaneous injections	Jiangsu Hengrui Medicine	Phase 1	33
SHR-1209	Jiangsu Hengrui Medicine	Phase 2	31